PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1522758
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1522758
Global Opioid Induced Constipation Drugs Market Size study, by Drug Type, by Prescription Type, by Distribution Channel and Regional Forecasts 2022-2032
The Global Opioid Induced Constipation (OIC) Drugs Market is valued approximately at USD 1.21 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.01 % over the forecast period 2024-2032. Opioid-induced constipation (OIC) arises primarily due to opioids activating enteric receptors, which subsequently heighten tonic non-propulsive contractions within the intestines, thereby increasing colonic fluid absorption and leading to stool desiccation. Furthermore, opioids tend to elevate the anal sphincter tone and lower the rectal sensory threshold, contributing to tougher stools and less frequent, inefficient defecation. This market encompasses various drugs and treatments designed to manage constipation induced by opioid usage. Growth and innovation within the pharmaceutical industry, driven by a substantial pool of health-conscious consumers, present opportunities for the OIC drugs market share. The market's expansion is anticipated to be propelled by emerging markets, improved healthcare infrastructure, unmet healthcare needs, increasing prevalence of chronic pain in adults, and a rising demand for novel drugs to manage OIC disorders.
The healthcare sector in emerging economies is evolving rapidly, spurred by a growing demand for enhanced healthcare services, significant government investments to upgrade healthcare infrastructure, and the development of the medical tourism industry. E-commerce has become an indispensable tool for businesses globally, driven by the consumer preference for online shopping over traditional purchasing methods. Various health apps with animations to educate the public about OIC and available treatment options have further contributed to the market growth. The demand for effective OIC medications extends beyond developed countries, reaching developing nations like China, Brazil, and India, fueling the market's growth. However, the side effects associated with OIC drugs and the high costs of novel pharmaceuticals, coupled with unfavorable reimbursement policies, act as restraints on market growth. On the contrary, rising R&D activities, increasing regulatory approvals, and higher investments in OIC research are expected to provide lucrative opportunities for market players. Additionally, the demand for novel therapeutics to treat OIC is projected to drive market growth further.
The Opioid-Induced Constipation Market is analyzed across North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. In 2023, North America dominate the market in terms of revenue due to the high prevalence of opioid prescriptions and the growing awareness of related side effects. The region's well-established healthcare infrastructure, coupled with advanced pharmaceutical research and development, supports a robust market for opioid-induced constipation treatments. Additionally, increasing patient awareness and a strong emphasis on addressing the adverse effects of opioid use drive demand for effective management solutions. The presence of major pharmaceutical companies and the availability of innovative therapies further contribute to North America's leading position in this market. Consequently, North America remains a key player in addressing opioid-induced constipation globally. Asia-Pacific is anticipated to grow at the highest rate during the forecast period, attributed to the increasing number of cancer cases, rising awareness campaigns, and investments in effective OIC drugs.
Major market players included in this report are:
- AstraZeneca
- Bausch Health Companies Inc.
- Cosmo Pharmaceuticals
- Dr. Reddy's Laboratories Ltd.
- Mallinckrodt plc
- Merck & Co., Inc.
- Novartis AG
- Shionogi & Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- RedHill Biopharma Ltd.
- Sandoz (Novartis AG)
- Daiichi Sankyo Co., Ltd.
- Pfizer Inc.
- Bayer AG
The detailed segments and sub-segment of the market are explained below:
By Drug Type:
- Mu-opioid Receptor Antagonists
- Chloride Channel-2 Activators
- Others
By Prescription Type:
- Over The Counter Drugs
- Prescribed Drugs
By Distribution Channel:
- Hospital Pharmacies
- Online Providers
- Drug Store and Retail Pharmacies
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Opioid Induced Constipation (OIC) Drugs Market Executive Summary
- 1.1. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Drug Type
- 1.3.2. By Prescription Type
- 1.3.3. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Opioid Induced Constipation (OIC) Drugs Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Opioid Induced Constipation (OIC) Drugs Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Increase in Chronic Pain Cases
- 3.1.2. Rise in Awareness and Education Programs
- 3.1.3. Growth in Pharmaceutical Innovations
- 3.2. Market Challenges
- 3.2.1. Side Effects of OIC Drugs
- 3.2.2. High Costs and Unfavorable Reimbursement Policies
- 3.3. Market Opportunities
- 3.3.1. Emerging Markets and Healthcare Infrastructure
- 3.3.2. Rising R&D Activities
- 3.3.3. Increase in Demand for Novel Therapeutics
Chapter 4. Global Opioid Induced Constipation (OIC) Drugs Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Drug Type 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Opioid Induced Constipation (OIC) Drugs Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Mu-opioid Receptor Antagonists
- 5.2.2. Chloride Channel-2 Activators
- 5.2.3. Others
Chapter 6. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Prescription Type 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Opioid Induced Constipation (OIC) Drugs Market: Prescription Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Over The Counter Drugs
- 6.2.2. Prescribed Drugs
Chapter 7. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Distribution Channel 2022-2032
- 7.1. Segment Dashboard
- 7.2. Global Opioid Induced Constipation (OIC) Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospital Pharmacies
- 7.2.2. Online Providers
- 7.2.3. Drug Store and Retail Pharmacies
Chapter 8. Global Opioid Induced Constipation (OIC) Drugs Market Size & Forecasts by Region 2022-2032
- 8.1. North America Opioid Induced Constipation (OIC) Drugs Market
- 8.1.1. U.S. Opioid Induced Constipation (OIC) Drugs Market
- 8.1.1.1. Drug Type breakdown size & forecasts, 2022-2032
- 8.1.1.2. Prescription Type breakdown size & forecasts, 2022-2032
- 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Opioid Induced Constipation (OIC) Drugs Market
- 8.1.2.1. Drug Type breakdown size & forecasts, 2022-2032
- 8.1.2.2. Prescription Type breakdown size & forecasts, 2022-2032
- 8.1.2.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.1.1. U.S. Opioid Induced Constipation (OIC) Drugs Market
- 8.2. Europe Opioid Induced Constipation (OIC) Drugs Market
- 8.2.1. U.K. Opioid Induced Constipation (OIC) Drugs Market
- 8.2.1.1. Drug Type breakdown size & forecasts, 2022-2032
- 8.2.1.2. Prescription Type breakdown size & forecasts, 2022-2032
- 8.2.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.2.2. Germany Opioid Induced Constipation (OIC) Drugs Market
- 8.2.3. France Opioid Induced Constipation (OIC) Drugs Market
- 8.2.4. Spain Opioid Induced Constipation (OIC) Drugs Market
- 8.2.5. Italy Opioid Induced Constipation (OIC) Drugs Market
- 8.2.6. Rest of Europe Opioid Induced Constipation (OIC) Drugs Market
- 8.2.1. U.K. Opioid Induced Constipation (OIC) Drugs Market
- 8.3. Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market
- 8.3.1. China Opioid Induced Constipation (OIC) Drugs Market
- 8.3.1.1. Drug Type breakdown size & forecasts, 2022-2032
- 8.3.1.2. Prescription Type breakdown size & forecasts, 2022-2032
- 8.3.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.3.2. India Opioid Induced Constipation (OIC) Drugs Market
- 8.3.3. Japan Opioid Induced Constipation (OIC) Drugs Market
- 8.3.4. Australia Opioid Induced Constipation (OIC) Drugs Market
- 8.3.5. South Korea Opioid Induced Constipation (OIC) Drugs Market
- 8.3.6. Rest of Asia Pacific Opioid Induced Constipation (OIC) Drugs Market
- 8.3.1. China Opioid Induced Constipation (OIC) Drugs Market
- 8.4. Latin America Opioid Induced Constipation (OIC) Drugs Market
- 8.4.1. Brazil Opioid Induced Constipation (OIC) Drugs Market
- 8.4.2. Mexico Opioid Induced Constipation (OIC) Drugs Market
- 8.4.3. Rest of Latin America Opioid Induced Constipation (OIC) Drugs Market
- 8.5. Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market
- 8.5.1. Saudi Arabia Opioid Induced Constipation (OIC) Drugs Market
- 8.5.2. South Africa Opioid Induced Constipation (OIC) Drugs Market
- 8.5.3. Rest of Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. AstraZeneca
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. Bausch Health Companies Inc.
- 9.3.3. Shionogi & Co., Ltd.
- 9.3.4. Cosmo Pharmaceuticals
- 9.3.5. Dr. Reddy's Laboratories Ltd.
- 9.3.6. Mallinckrodt plc
- 9.3.7. Merck & Co., Inc.
- 9.3.8. Novartis AG
- 9.3.9. Takeda Pharmaceutical Company Limited
- 9.3.10. Teva Pharmaceutical Industries Ltd.
- 9.3.11. RedHill Biopharma Ltd.
- 9.3.12. Sandoz (Novartis AG)
- 9.3.13. Daiichi Sankyo Co., Ltd.
- 9.3.14. Pfizer Inc.
- 9.3.15. Bayer AG
- 9.3.1. AstraZeneca
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
